Pfizer
Yan Weng is an experienced professional in clinical pharmacology with a strong background in drug metabolism and toxicology. Currently serving as Senior Director of Clinical Pharmacology at Pfizer from October 2020 to June 2025, Yan provides scientific leadership and innovation within a therapeutic area portfolio while managing Clinical Pharmacology Leads and supporting their career development. Previously, Yan held roles as Director and Associate Director of Clinical Pharmacology, focusing on program leadership, Gene Therapy, and immunogenicity. Earlier experience includes serving as a Research Scientist at the Wadsworth Center, contributing expertise in pharmacokinetics and DMPK. Yan holds a Ph.D. in Toxicology/Drug Metabolism from the University at Albany and a Master’s degree in Environmental Sciences from Xiamen University.
This person is not in any teams
This person is not in any offices
Pfizer
605 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.